Cardioprotection by metabolic shut-down and gradual wake-up

Journal of Molecular and Cellular Cardiology

Volumn 46, Issue 6, 2009, Pages 804-810

  Burwell, Lindsay S ^a   Nadtochiy, Sergiy M ^a   Brookes, Paul S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardioprotection; Ischemic preconditioning; Mitochondria; Nitric oxide; Reperfusion injury

Indexed keywords

3 NITROPROPIONIC ACID; ADENOSINE TRIPHOSPHATE; AMOBARBITAL; ANTIOXIDANT; CALCIUM ION; CAPSAICIN; CARBON MONOXIDE; CARIPORIDE; CYCLOSPORIN A; CYTOCHROME C OXIDASE; DIAZOXIDE; HALOTHANE; ISOFLURANE; MALONIC ACID; MENADIONE; METFORMIN; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MYXOTHIAZOL; N AMIDINO 1,4 DIMETHYL 1H INDOLE 2 CARBOXAMIDE; NITRIC OXIDE; OXYGEN; RANOLAZINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; S NITROSOTHIOL; SANGLIFEHRIN A; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UNINDEXED DRUG;

CELL DEATH; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; GLYCOLYSIS; HEART FUNCTION; HEART INFARCTION PREVENTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; GLYCOLYSIS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA; MODELS, BIOLOGICAL; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE;

EID: 67349236041     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2009.02.026     Document Type: Review

References (98)

1. Brookes P.S., Yoon Y., Robotham J.L., Anders M.W., and Sheu S.S. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am. J. Physiol. Cell Physiol. 287 (2004) C817-C833
2. Di Lisa F., and Bernardi P. Mitochondria and ischemia-reperfusion injury of the heart: fixing a hole. Cardiovasc. Res. 70 (2006) 191-199
3. Karmazyn M. The myocardial sodium-hydrogen exchanger (NHE) and its role in mediating ischemic and reperfusion injury. Keio J. Med. 47 (1998) 65-72
4. Griffiths E.J., and Halestrap A.P. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem. J. 307 Pt 1 (1995) 93-98
5. Kim J.S., Ohshima S., Pediaditakis P., and Lemasters J.J. Nitric oxide: a signaling molecule against mitochondrial permeability transition- and pH-dependent cell death after reperfusion. Free Radic. Biol. Med. 37 (2004) 1943-1950
6. Armstrong J.S. Mitochondrial membrane permeabilization: the sine qua non for cell death. Bioessays 28 (2006) 253-260
7. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 341 Pt 2 (1999) 233-249
8. Borutaite V., Mildaziene V., Brown G.C., and Brand M.D. Control and kinetic analysis of ischemia-damaged heart mitochondria: which parts of the oxidative phosphorylation system are affected by ischemia?. Biochim. Biophys. Acta 1272 (1995) 154-158
9. Akar F.G., Aon M.A., Tomaselli G.F., and O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J. Clin. Invest. 115 (2005) 3527-3535
10. Yamamoto S., Matsui K., and Ohashi N. Protective effect of Na+ /H+ exchange inhibitor, SM-20550, on impaired mitochondrial respiratory function and mitochondrial Ca2+ overload in ischemic/reperfused rat hearts. J. Cardiovasc. Pharmacol. 39 (2002) 569-575
11. Chakrabarti S., Hoque A.N., and Karmazyn M. A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide). J. Mol. Cell Cardiol. 29 (1997) 3169-3174
12. Liu Y., Sato T., O'Rourke B., and Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?. Circulation 97 (1998) 2463-2469
13. Holmuhamedov E.L., Wang L., and Terzic A. ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria. J. Physiol. (Lond.) 519 Pt 2 (1999) 347-360
14. Drose S., Brandt U., and Hanley P.J. K+-independent actions of diazoxide question the role of inner membrane KATP channels in mitochondrial cytoprotective signaling. J. Biol. Chem. 281 (2006) 23733-23739
15. Clarke S.J., McStay G.P., and Halestrap A.P. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J. Biol. Chem. 277 (2002) 34793-34799
16. Horwitz L.D., Fennessey P.V., Shikes R.H., and Kong Y. Marked reduction in myocardial infarct size due to prolonged infusion of an antioxidant during reperfusion. Circulation 89 (1994) 1792-1801
17. Brookes P.S., Salinas E.P., Darley-Usmar K., Eiserich J.P., Freeman B.A., Darley-Usmar V.M., et al. Concentration-dependent effects of nitric oxide on mitochondrial permeability transition and cytochrome c release. J. Biol. Chem. 275 (2000) 20474-20479
18. Cohen M.V., Yang X.M., and Downey J.M. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 115 (2007) 1895-1903
19. Burwell L.S., and Brookes P.S. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid. Redox. Signal 10 (2008) 579-599
20. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 85 (2005) 1093-1129
21. Kussmaul L., and Hirst J. The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7607-7612
22. Blinova K., Levine R.L., Boja E.S., Griffiths G.L., Shi Z.D., Ruddy B., et al. Mitochondrial NADH fluorescence is enhanced by complex I binding. Biochemistry 47 (2008) 9636-9645
23. Jones D.P. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295 (2008) C849-C868
24. Fontaine E., and Bernardi P. Progress on the mitochondrial permeability transition pore: regulation by complex I and ubiquinone analogs. J. Bioenerg. Biomembr. 31 (1999) 335-345
25. Chance B. Reaction of oxygen with the respiratory chain in cells and tissues. J. Gen. Physiol. 49 (1965) 163-195
26. Chen Q., Hoppel C.L., and Lesnefsky E.J. Blockade of electron transport before cardiac ischemia with the reversible inhibitor amobarbital protects rat heart mitochondria. J. Pharmacol. Exp. Ther. 316 (2006) 200-207
27. Lesnefsky E.J., Chen Q., Moghaddas S., Hassan M.O., Tandler B., and Hoppel C.L. Blockade of electron transport during ischemia protects cardiac mitochondria. J. Biol. Chem. 279 (2004) 47961-47967
28. Burwell L.S., Nadtochiy S.M., Tompkins A.J., Young S., and Brookes P.S. Direct evidence for S-nitrosation of mitochondrial complex I. Biochem. J. 394 (2006) 627-634
29. Nadtochiy S.M., Burwell L.S., and Brookes P.S. Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2-mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J. Mol. Cell Cardiol. 42 (2007) 812-825
30. McCormack J.G., Stanley W.C., and Wolff A.A. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen. Pharmacol. 30 (1998) 639-645
31. Wyatt K.M., Skene C., Veitch K., Hue L., and McCormack J.G. The antianginal agent ranolazine is a weak inhibitor of the respiratory complex I, but with greater potency in broken or uncoupled than in coupled mitochondria. Biochem. Pharmacol. 50 (1995) 1599-1606
32. D'Alonzo A.J., Grover G.J., Darbenzio R.B., Hess T.A., Sleph P.G., Dzwonczyk S., et al. In vitro effects of capsaicin: antiarrhythmic and antiischemic activity. Eur. J. Pharmacol. 272 (1995) 269-278
33. Satoh T., Miyoshi H., Sakamoto K., and Iwamura H. Comparison of the inhibitory action of synthetic capsaicin analogues with various NADH-ubiquinone oxidoreductases. Biochim. Biophys. Acta 1273 (1996) 21-30
34. Bains R., Moe M.C., Larsen G.A., Berg-Johnsen J., and Vinje M.L. Volatile anaesthetics depolarize neural mitochondria by inhibition of the electron transport chain. Acta Anaesthesiol. Scand. 50 (2006) 572-579
35. Hanley P.J., Ray J., Brandt U., and Daut J. Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J. Physiol. 544 (2002) 687-693
36. Yue Y., Krenz M., Cohen M.V., Downey J.M., and Critz S.D. Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H590-H595
37. Brunmair B., Staniek K., Gras F., Scharf N., Althaym A., Clara R., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions. Diabetes 53 (2004) 1052-1059
38. Kawabata H., and Ishikawa K. Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. Hypertens. Res. 26 (2003) 107-110
39. Hill B.G., and Darley-Usmar V.M. S-nitrosation and thiol switching in the mitochondrion: a new paradigm for cardioprotection in ischaemic preconditioning. Biochem. J. 412 (2008) e11-e13
40. Shiva S., Sack M.N., Greer J.J., Duranski M., Ringwood L.A., Burwell L., et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J. Exp. Med. 204 (2007) 2089-2102
41. Ardehali H., Chen Z., Ko Y., Mejia-Alvarez R., and Marban E. Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11880-11885
42. Hirata T., Fukuse T., Ishikawa S., Hanaoka S., Chen Q., Shoji T., et al. "Chemical preconditioning" by 3-nitropropionate reduces ischemia-reperfusion injury in cardiac-arrested rat lungs. Transplantation 71 (2001) 352-359
43. Riepe M.W., Esclaire F., Kasischke K., Schreiber S., Nakase H., Kempski O., et al. Increased hypoxic tolerance by chemical inhibition of oxidative phosphorylation: "chemical preconditioning". J. Cereb. Blood Flow Metab. 17 (1997) 257-264
44. Wojtovich A.P., and Brookes P.S. The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning. Biochim. Biophys. Acta 1777 (2008) 882-889
45. Wojtovich A.P., and Brookes P.S. The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial K(ATP) channels. Basic Res. Cardiol. 104 (2009) 121-129
46. Shiva S., Crawford J.H., Ramachandran A., Ceaser E.K., Hillson T., Brookes P.S., et al. Mechanisms of the interaction of nitroxyl with mitochondria. Biochem. J. 379 (2004) 359-366
47. Pagliaro P., Mancardi D., Rastaldo R., Penna C., Gattullo D., Miranda K.M., et al. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic. Biol. Med. 34 (2003) 33-43
48. Paolocci N., Jackson M.I., Lopez B.E., Miranda K., Tocchetti C.G., Wink D.A., et al. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol. Ther. 113 (2007) 442-458
49. Gutman M., Kearney E.B., and Singer T.P. Control of succinate dehydrogenase in mitochondria. Biochemistry 10 (1971) 4763-4770
50. Dzeja P.P., Bast P., Ozcan C., Valverde A., Holmuhamedov E.L., Van Wylen D.G., et al. Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1048-H1056
51. Schafer G., Wegener C., Portenhauser R., and Bojanovski D. Diazoxide, an inhibitor of succinate oxidation. Biochem. Pharmacol. 18 (1969) 2678-2681
52. Pasdois P., Beauvoit B., Tariosse L., Vinassa B., Bonoron-Adele S., and Santos P.D. MitoK(ATP)-dependent changes in mitochondrial volume and in complex II activity during ischemic and pharmacological preconditioning of Langendorff-perfused rat heart. J. Bioenerg. Biomembr. 38 (2006) 101-112
53. Vanden Hoek T.L., Becker L.B., Shao Z., Li C., and Schumacker P.T. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J. Biol. Chem. 273 (1998) 18092-18098
54. Ludwig L.M., Tanaka K., Eells J.T., Weihrauch D., Pagel P.S., Kersten J.R., et al. Preconditioning by isoflurane is mediated by reactive oxygen species generated from mitochondrial electron transport chain complex III. Anesth. Analg. 99 (2004) 1308-1315
55. Kabir A.M., Clark J.E., Tanno M., Cao X., Hothersall J.S., Dashnyam S., et al. Cardioprotection initiated by reactive oxygen species is dependent on activation of PKCepsilon. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1893-H1899
56. Brunori M., Forte E., Arese M., Mastronicola D., Giuffre A., and Sarti P. Nitric oxide and the respiratory enzyme. Biochim. Biophys. Acta 1757 (2006) 1144-1154
57. Cooper C.E., and Giulivi C. Nitric oxide regulation of mitochondrial oxygen consumption II: molecular mechanism and tissue physiology. Am. J. Physiol. Cell Physiol. 292 (2007) C1993-C2003
58. Giulivi C., Kato K., and Cooper C.E. Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiology. Am. J. Physiol. Cell Physiol. 291 (2006) C1225-C1231
59. Jones S.P., and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell Cardiol. 40 (2006) 16-23
60. Castello P.R., David P.S., McClure T., Crook Z., and Poyton R.O. Mitochondrial cytochrome oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing and hypoxic signaling in eukaryotes. Cell Metab. 3 (2006) 277-287
61. D'Amico G., Lam F., Hagen T., and Moncada S. Inhibition of cellular respiration by endogenously produced carbon monoxide. J. Cell Sci. 119 (2006) 2291-2298
62. Pearce L.L., Lopez M.E., Martinez-Bosch S., and Peterson J. Antagonism of nitric oxide toward the inhibition of cytochrome c oxidase by carbon monoxide and cyanide. Chem. Res. Toxicol. 21 (2008) 2073-2081
63. Clark J.E., Naughton P., Shurey S., Green C.J., Johnson T.R., Mann B.E., et al. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ. Res. 93 (2003) e2-e8
64. Cooper C.E., and Brown G.C. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulfide: chemical mechanism and physiological significance. J. Bioenerg. Biomembr. 40 (2008) 533-539
65. Nicholson R.A., Roth S.H., Zhang A., Zheng J., Brookes J., Skrajny B., et al. Inhibition of respiratory and bioenergetic mechanisms by hydrogen sulfide in mammalian brain. J. Toxicol. Environ. Health A 54 (1998) 491-507
66. Elrod J.W., Calvert J.W., Morrison J., Doeller J.E., Kraus D.W., Tao L., et al. Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15560-15565
67. Kodde I.F., van der S.J., Smolenski R.T., and de Jong J.W. Metabolic and genetic regulation of cardiac energy substrate preference. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 146 (2007) 26-39
68. Vogt A.M., Poolman M., Ackermann C., Yildiz M., Schoels W., Fell D.A., et al. Regulation of glycolytic flux in ischemic preconditioning. A study employing metabolic control analysis. J. Biol. Chem. 277 (2002) 24411-24419
69. McDonald L.J., and Moss J. Stimulation by nitric oxide of an NAD linkage to glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6238-6241
70. Mohr S., Stamler J.S., and Brune B. Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment. J. Biol. Chem. 271 (1996) 4209-4214
71. Batthyany C., Schopfer F.J., Baker P.R., Duran R., Baker L.M., Huang Y., et al. Reversible post-translational modification of proteins by nitrated fatty acids in vivo. J. Biol. Chem. 281 (2006) 20450-20463
72. Nadtochiy SM, Baker PR, Freeman BA, Brookes PS. Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning: implications for cardioprotection. Cardiovasc Res in press, doi:10.1093/cvr/cvn323.
73. Takeuchi K., Cao-Danh H., Friehs I., Glynn P., D'Agostino D., Simplaceanu E., et al. Administration of fructose 1,6-diphosphate during early reperfusion significantly improves recovery of contractile function in the postischemic heart. J. Thorac. Cardiovasc. Surg. 116 (1998) 335-343
74. Marchionni N., Conti A., De A.W., Di B.M., Ferrucci L., Lombardi A., et al. Hemodynamic and electrocardiographic effects of fructose-1,6-diphosphate in acute myocardial infarction. Am. J. Cardiol. 56 (1985) 266-269
75. Yabe K., Nasa Y., Sato M., Iijima R., and Takeo S. Preconditioning preserves mitochondrial function and glycolytic flux during an early period of reperfusion in perfused rat hearts. Cardiovasc. Res. 33 (1997) 677-685
76. Peralta C., Bartrons R., Riera L., Manzano A., Xaus C., Gelpi E., et al. Hepatic preconditioning preserves energy metabolism during sustained ischemia. Am. J. Physiol. Gastrointest. Liver Physiol. 279 (2000) G163-G171
77. Jones N.M., and Bergeron M. Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. J. Cereb. Blood Flow Metab. 21 (2001) 1105-1114
78. Zuurbier C.J., Eerbeek O., and Meijer A.J. Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H496-H499
79. Brooks G.A., Dubouchaud H., Brown M., Sicurello J.P., and Butz C.E. Role of mitochondrial lactate dehydrogenase and lactate oxidation in the intracellular lactate shuttle. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1129-1134
80. Brooks G.A. Lactate shuttles in nature. Biochem. Soc. Trans. 30 (2002) 258-264
81. Sun L., Shukair S., Naik T.J., Moazed F., and Ardehali H. Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol. Cell Biol. 28 (2008) 1007-1017
82. Borchi E, Parri M, Papucci L, Becatti M, Nassi N, Nassi P, et al. Role of NADPH oxidase in H9c2 cardiac muscle cells exposed to simulated ischemia-reperfusion. J Cell Mol Med in press, doi:10.1111/j.1582-4934.2008.00485.x.
83. Zuurbier C.J., Eerbeek O., Goedhart P.T., Struys E.A., Verhoeven N.M., Jakobs C., et al. Inhibition of the pentose phosphate pathway decreases ischemia-reperfusion-induced creatine kinase release in the heart. Cardiovasc. Res. 62 (2004) 145-153
84. Ozcan C., Holmuhamedov E.L., Jahangir A., and Terzic A. Diazoxide protects mitochondria from anoxic injury: implications for myopreservation. J. Thorac. Cardiovasc. Surg. 121 (2001) 298-306
85. Cole R.P., Sukanek P.C., Wittenberg J.B., and Wittenberg B.A. Mitochondrial function in the presence of myoglobin. J. Appl. Physiol. 53 (1982) 1116-1124
86. Brookes P.S., Kraus D.W., Shiva S., Doeller J.E., Barone M.C., Patel R.P., et al. Control of mitochondrial respiration by NO*, effects of low oxygen and respiratory state. J. Biol. Chem. 278 (2003) 31603-31609
87. Hoffman D.L., Salter J.D., and Brookes P.S. Response of mitochondrial reactive oxygen species generation to steady-state oxygen tension: implications for hypoxic cell signaling. Am. J. Physiol. Heart Circ. Physiol. 292 (2007) H101-H108
88. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H579-H588
89. Stadnicka A., Marinovic J., Ljubkovic M., Bienengraeber M.W., and Bosnjak Z.J. Volatile anesthetic-induced cardiac preconditioning. J. Anesth. 21 (2007) 212-219
90. Krolikowski J.G., Bienengraeber M., Weihrauch D., Warltier D.C., Kersten J.R., and Pagel P.S. Inhibition of mitochondrial permeability transition enhances isoflurane-induced cardioprotection during early reperfusion: the role of mitochondrial KATP channels. Anesth. Analg. 101 (2005) 1590-1596
91. Jahangir A., Sagar S., and Terzic A. Aging and cardioprotection. J. Appl. Physiol. 103 (2007) 2120-2128
92. Tanaka K., Kehl F., Gu W., Krolikowski J.G., Pagel P.S., Warltier D.C., et al. Isoflurane-induced preconditioning is attenuated by diabetes. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H2018-H2023
93. Murphy E., and Steenbergen C. Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 75 (2007) 478-486
94. Riess M.L., Stowe D.F., and Warltier D.C. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside?. Am. J. Physiol. Heart Circ. Physiol. 286 (2004) H1603-H1607
95. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
96. Gerlach M., Riederer P., Przuntek H., and Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208 (1991) 273-286
97. Beal M.F., Brouillet E., Jenkins B., Henshaw R., Rosen B., and Hyman B.T. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61 (1993) 1147-1150
98. Brouillet E., Jenkins B.G., Hyman B.T., Ferrante R.J., Kowall N.W., Srivastava R., et al. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. 60 (1993) 356-359